EC Neurology

Editorial Volume 16 Issue 11 - 2024

Depressive and Anxious Mood Disorder at COVID Long: A Case Report

José Augusto Camargo1,2* and Stéfani Augustoli Morcillo3

1Neuroscience Research Institute, Newclin Medical Clinic, Sorocaba, São Paulo, Brazil
2Professor, Faculty of Medicine, Pontifical Catholic University of Sao Paulo, Brazil
3Medical Student, Faculty of Medicine, Pontifical Catholic University of Sao Paulo, Brazil

*Corresponding Author: José Augusto Camargo, Neuroscience Research Institute, Newclin Medical Clinic, Sorocaba, São Paulo, Brazil.
Received: September 25, 2024; Published: October 08, 2024



Depression and anxiety are prevalent diseases and have their clinical diagnosis. The etiologies and classifications are diverse, and both have been associated with some types of infections, including COVID-19. We report a case of a 49-year-old man who developed a depressive and anxious mood disorder as a sequel to a long covid infection.

 Keywords: Long Covid; Depression; Anxiety; PET/CT

  1. Secretarias Estaduais de Saúde. Painel de casos de doença pelo coronavírus 2019 (COVID-19) no Brasil pelo Ministério da Saúde (MS) (2024).
  2. Teodoro EF., et al. “DSM-5 and mood disorders: a critical analysis in the light of psychoanalytic theory”. PePsic 23 (2021): 52-78.
  3. Guan J., et al. “Effects and neural mechanisms of different physical activity on major depressive disorder based on cerebral multimodality monitoring: a narrative review”. Frontiers in Human Neuroscience 18 (2024): 1406670.
  4. Katsushima M and Shimizu E. “Brief cognitive behavioral therapy for depression and anxiety in patients with schizophrenia in psychiatric home nursing service: Pilot randomized controlled trial”. Behavioral Sciences 8 (2024): 680.
  5. Yirmiya R. “The inflammatory underpinning of depression: An historical perspective”. Brain, Behavior, and Immunity 122 (2024): 433-443.
  6. Cepeda Y., et al. “Regulatory T cells administration reduces anxiety-like behavior in mice submitted to chronic restraint stress”. Frontiers in Cellular Neuroscience 18 (2024): 1406832.
  7. Cooper ZW., et al. “Addressing depression and comorbid health conditions through solution-focused brief therapy in an integrated care setting: a randomized clinical trial”. BMC Primary Care 1 (2024): 313.
  8. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorder (DSM-5) 5 (2013): 87-122.
  9. Fernandes MA., et al. “Prevalence of anxiety disorders as a cause of workers’ absence”. Revista Brasileira de Enfermagem 5 (2018): 2213-2220.
  10. Alvarado-Esquivel C., et al. “Toxoplasma gondii infection and mixed anxiety and depressive disorder: a case-control seroprevalence study in Durango, Mexico”. Journal of Clinical Medicine Research 7 (2016): 519-523.
  11. Stumpf BP., et al. “Infecções virais e depressão”. Jornal Brasileiro de Psiquiatria 2 (2006).
  12. Organização Pan-Americana de Saúde. COVID-19 eliminou uma década de progresso na expectativa de vida global (2024).
  13. Governo Brasileiro. Painel Coronavírus. DATASUS (2024).
  14. Vu TT., et al. “Prevalence and symptom profile of Long COVID among schoolchildren in Vietnam”. Viruses7 (2024): 1021.
  15. Wentz E., et al. “Cohort profile: the Johns Hopkins COVID Long Study (JHCLS)-a US nationwide prospective cohort study”. BMJ Open 6 (2024): e077742.
  16. Haag L., et al. “Baseline Characteristics in the Remote Diet Intervention to REduce long-COVID Symptoms Trial (ReDIRECT)”. NIHR Open Research 4 (2024): 7.
  17. Carpio-Orantes LD., et al. “Clinical-epidemiological characterization of patients with long COVID in Mexico”. Gaceta Médica de México 2 (2024): 136-143.
  18. Xu J., et al. “Adult outpatients with long COVID infected with SARS-CoV-2 Omicron variant. Part 1: Oral microbiota alterations”. American Journal of Medicine (2024): S0002-9343(24)00489-3.
  19. El-Toukhy S., et al. “Study of postacute sequelae of COVID-19 using digital wearables: Protocol for a prospective longitudinal observational study”. JMIR Research Protocols 13 (2024): e57382.
  20. Butzin-Dozier Z., et al. “Predicting Long COVID in the National COVID Cohort Collaborative Using Super Learner: Cohort Study”. JMIR Public Health and Surveillance 10 (2024): e53322.
  21. Perez O., et al. “Long-term patient symptoms and quality of life in adults after COVID-19: A real-life study”. Open Respiratory Archives 3 (2024): 100336.
  22. Dietz TK and Brondstater KN. “Long COVID management: a mini review of current recommendations and underutilized modalities”. Frontiers in Medicine 11 (2024): 1430444.
  23. Kozłowski P., et al. “Long COVID definition, symptoms, risk factors, epidemiology and autoimmunity: A narrative review”. American Journal of Medicine Open 11 (2024): 100068.
  24. Camargo JA and Morcillo SA. “Post-COVID-19 Sydenham Chorea: A case report”. The Open Neurology Journal (2023).
  25. Camargo JA and Morcillo SA. “Post COVID-19 Parkinsonism: A case report”. Annals of Clinical and Medical Case Reports 15 (2023): 1-4.
  26. Morassi M., et al. “SARS-CoV-2-related encephalitis with prominent parkinsonism: clinical and FDG-PET correlates in two patients”. Journal of Neurology 11 (2021): 3980-3987.
  27. Camargo JA., et al. “Mental health disorder post-COVID-19 infection: A case report”. Journal of Psychiatry Research Reviews and Reports 4 (2024): 1-3.
  28. Julide T., et al. “Cognitive impairment in long-COVID”. Ideggyogyaszati Szemle 5-6 (2024): 151-159.
  29. Taquet M., et al. “Cognitive and psychiatric symptom trajectories 2-3 years after hospital admission for COVID-19: a longitudinal, prospective cohort study in the UK”. The Lancet Psychiatry 9 (2024): 696-708.
  30. Thomas M., et al. “A prospective cohort study on cognitive and psychological outcomes in COVID-19 ICU survivors at 3 months of follow up”. Frontiers in Medicine 11 (2024): 1288761.
  31. Radulovic D., et al. “A complex relationship between quality of life, anxiety, and depression among general population during second year of COVID-19 pandemic: A population-based study”. Journal of Clinical Medicine 13 (2024): 3874.
  32. Cahan J., et al. “Cognitive functioning in patients with neuro-PASC: the role of fatigue, mood, and hospitalization status”. Frontiers in Neurology 15 (2024): 1401796.
  33. Zang C., et al. “Identification of risk factors of Long COVID and predictive modeling in the RECOVER EHR cohorts”. Communications Medicine 1 (2024): 130.
  34. Meca-García JM., et al. “Neuropsychiatric symptoms of patients two years after experiencing severe COVID-19: A mixed observational study”. Medicina Clínica (2024): S0025-7753(24)00360-9.
  35. Almeria M., et al. “Neurocognitive and neuropsychiatric sequelae in long COVID-19 infection”. Brain Sciences 6 (2024): 604.
  36. Navarra-Ventura G., et al. “Occurrence, co-occurrence, and persistence of symptoms of depression and post-traumatic stress disorder in survivors of COVID-19 critical illness”. European Journal of Psychotraumatology 1 (2024): 2363654.
  37. Almeria M., et al. “Long neurocognitive and neuropsychiatric sequelae in participants with post-COVID-19 infection: A longitudinal study”. Neurology International 4 (2024): 853-868.
  38. Pietrzak P and Hanke W. “The long COVID and its mental health manifestations - the review of literature”. International Journal of Occupational Medicine and Environmental Health 3 (2024): 360-380.
  39. Reuschke D., et al. “Impacts of Long COVID on workers: A longitudinal study of employment exit, work hours and mental health in the UK”. PLoS One6 (2024): e0306122.
  40. Duricka D and Liu L. “Reduction of long COVID symptoms after stellate ganglion block: A retrospective chart review study”. Autonomic Neuroscience 254 (2024): 103195.
  41. Li AY., et al. “Emerging trends in management of long COVID with a focus on pulmonary rehabilitation: A review”. Clinical Respiratory Journal 5 (2024): e13777.
  42. Chou R., et al. “Long COVID definitions and models of care: A scoping review”. Annals of Internal Medicine 7 (2024): 929-940.
  43. Dudouet P., et al. “Aortic 18F-FDG PET/CT hypermetabolism in patients with long COVID: a retrospective study”. Clinical Microbiology and Infection 12 (2021): 1873-1875.
  44. Chen LL., et al. “Investigating the potential added value of [18F] FDG-PET/CT in long COVID patients with persistent symptoms: a proof of concept study”. Nuclear Medicine Communications 6 (2023): 495-501.
  45. Rudroff T., et al. “18F-FDG-PET imaging for post-COVID-19 brain and skeletal muscle alterations”. Viruses11 (2021): 2283.
  46. Tiraboschi P., et al. “Postinfectious neurologic complications in COVID-19: A complex case report”. Journal of Nuclear Medicine 8 (2021): 1171-1176.
  47. Sollini M., et al. “Long COVID hallmarks on [18F] FDG-PET/CT: a case-control study”. European Journal of Nuclear Medicine and Molecular Imaging 10 (2021): 3187-3197.
  48. Cull O., et al. “Radiological markers of neurological manifestations of post-acute sequelae of SARS-CoV-2 infection: a mini-review”. Frontiers in Neurology 14 (2023): 1233079.
  49. Ferrucci R., et al. “Brain positron emission tomography (PET) and cognitive abnormalities one year after COVID-19”. Journal of Neurology 4 (2023): 1823-1834.
  50. Delorme C., et al. “CoCo-Neurosciences study group and COVID SMIT PSL study group. COVID-19-related encephalopathy: a case series with brain FDG-positron-emission tomography/computed tomography findings”. European Journal of Neurology 12 (2020): 2651-2657.

José Augusto Camargo and Stéfani Augustoli Morcillo. “Depressive and Anxious Mood Disorder at COVID Long: A Case Report”. EC Neurology  16.11 (2024): 01-07.

ECronicon Journal

Our Services

Quick Links

Information

Creative Commons LicenseOpen Access by ECronicon is licensed under a Creative Commons Attribution 4.0 International License
Based on a work at www.ecronicon.net